GHK-Cu Copper Peptide for Androgenetic Alopecia

Verdict: No reliable evidence it regrows hair

There is no sound clinical evidence that GHK-Cu copper peptide treats androgenetic alopecia. No controlled trial has ever tested copper peptide on its own for hair loss, and regulators class it as a cosmetic ingredient, not an approved hair-loss treatment.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

This earns a Counter-Evidence (Tier D) grade because the human data collapse on close inspection. The single randomized, double-blind, placebo-controlled trial (Lee 2016, n=45; PMID 27489425) did show more hair, but it tested a GHK peptide combined with 5-aminolevulinic acid — copper is never mentioned, and the co-agent makes any peptide-specific effect impossible to isolate. The only other human report (PMID 40225275, n=7, uncontrolled) tattooed a minoxidil + dutasteride + copper-peptide mixture into the scalp; minoxidil and dutasteride are the proven actives, and there is no control arm.

The remaining support is preclinical: cultured cells and ex-vivo follicles (PMID 17703734), C3H mice (PMID 1809108), and two mechanistic reviews by the molecule's discoverer, which carry an intellectual conflict of interest (PMID 29986520, PMID 18644225). Plausible biology — stimulating dermal papilla cells, suppressing TGF-β1 — is not the same as a clinical effect in patients.

Regulators and clinics reinforce this. The FDA treats copper peptides as cosmetic ingredients and approves only minoxidil and finasteride for hair loss; EFSA's copper claims concern the dietary mineral and pigmentation, not topical GHK-Cu; and the NHS lists only finasteride and minoxidil for male pattern baldness without mentioning copper peptide. The NIH Office of Dietary Supplements covers dietary copper only and does not address this use.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.46
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
67%
Broadly consistent
Evidence level
E7
Single small RCT

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.462
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — | C→D 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth
PMID: 27489425 2016 RCT (double-blind, placebo-controlled) n = 45
Finding: Hair count increase over 6 months was +52.6 (Group A, p<0.05), +71.5 (Group B, p<0.05), and +9.6 (placebo, NS); 6-month ratio change 2.38 (Group B) vs 1.21 (placebo), p<0.05. No adverse events. IMPORTANT: this is a GHK (glycyl-histidyl-lysine) peptide combined with 5-ALA — copper (Cu) is NOT mentioned in the formulation; it is NOT pure GHK-Cu and the 5-ALA co-agent confounds attribution to the peptide alone.
🟠 Limited quality Effect size: MD vs placebo approx +61.9 hairs (Group B) / +43.0 hairs (Group A) at 6 months; small absolute counts, single-center, n=45
View on PubMed
Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators
PMID: 40225275 2025 Retrospective case series (uncontrolled) n = 7
Finding: Median TSAR 26.5%; 71.4% (5/7) achieved >10% regrowth; top-quadrant SALT fell from 40.0% to 7.5% (p<0.001). IMPORTANT: copper peptide is ONE of THREE agents — minoxidil and dutasteride are the established, proven actives; this design cannot isolate any copper-peptide-specific effect, and there is no control arm.
🟠 Limited quality Effect size: Median 26.5% area regrowth (combination), NOT attributable to copper peptide alone; n=7, no control
View on PubMed
The effect of tripeptide-copper complex on human hair growth in vitro
PMID: 17703734 2007 In vitro / ex vivo (laboratory)
Finding: AHK-Cu stimulated elongation of human hair follicles ex vivo and proliferation of DPCs in vitro, and reduced DPC apoptosis. Authors conclude 'AHK-Cu promotes the growth of human hair follicles' via DPC proliferation/anti-apoptosis. This is mechanistic lab evidence only — NOT a clinical efficacy demonstration in patients with androgenetic alopecia.
Effect size: Cellular/follicle-organ-culture endpoints only; no human clinical outcome
View on PubMed
The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice
PMID: 1809108 1991 Animal study (C3H mice)
Finding: Peptide copper complexes stimulated hair follicle growth in C3H mice (foundational preclinical work supporting copper-peptide hair effects). No PubMed abstract available; design and conclusion confirmed from title and journal record. Animal model only — does not establish efficacy in human androgenetic alopecia.
🟠 Limited quality Effect size: Murine hair-follicle endpoint only; not quantifiable for human AGA
View on PubMed
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
PMID: 29986520 2018 Narrative review
Finding: Review (Pickart & Margolina) summarizing GHK-Cu's broad gene-modulating, anti-inflammatory, TGF-beta1-suppressing, collagen-stimulating and angiogenic (VEGF) actions, with proposed relevance to skin/hair/tissue repair. Mechanistic/hypothesis-generating only; provides NO clinical efficacy data for androgenetic alopecia. Authored by the GHK-Cu discoverer (potential intellectual COI).
🟠 Limited quality Effect size: N/A (review)
View on PubMed
The human tri-peptide GHK and tissue remodeling
PMID: 18644225 2008 Narrative review
Finding: Review (Pickart) describing GHK-Cu's wound-healing, anti-inflammatory, collagen/elastin-stimulating, and cell-proliferative actions, mentioning improved hair transplant success among applications. Mechanistic background only; NO controlled clinical evidence for androgenetic alopecia. Author is the GHK-Cu discoverer (intellectual COI).
🟠 Limited quality Effect size: N/A (review)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Copper peptides (copper tripeptide-1) are used as ingredients in cosmetic products; no copper peptide has FDA approval as a drug for hair loss, and the only FDA-approved hair-loss drug ingredients are minoxidil (topical OTC) and finasteride (oral Rx). source↗
L4b EU EFSA
Neutral
Copper contributes to normal hair pigmentation; copper contributes to the maintenance of normal connective tissues. source↗
L4c UK NHS
Neutral
Most hair loss does not need treatment ... Finasteride and minoxidil are the main treatments for male pattern baldness. ... These treatments do not work for everyone and only work for as long as they're used. source↗
L4d TW TFDA / 衛福部
Cautious
美國FDA所認可具有療效之生髮成分只有三種:外用的Minoxidil(落建)及口服的Finasteride(柔沛)與Dutasteride(新髮靈),台灣衛服部的認定標準跟美國FDA完全一致。 source↗
L5a NIH Office of Dietary Supplements
Neutral
Copper is an essential trace element ... Copper toxicity is rare in the general population. The Tolerable Upper Intake Level (UL) for adults is 10,000 mcg (10 mg)/day from food and supplements. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-androgenetic-alopecia-INT-copper-peptide-001 繁體中文版 →